ClinicalTrials.gg
SuspendedNCT00747669Updated Mar 23, 2012

Pharmacokinetic Study of Synera™ in Neonates and Infants

A Phase 4 interventional study of lidocaine 70mg and tetracaine 70mg topical patch in Pain, sponsored by ZARS Pharma Inc.. Suspended at 1 site in United States. Open to participants aged Up to 4 Months. Per ClinicalTrials.gov, last updated 2012-03-23.

Sponsored by ZARS Pharma Inc. · Phase 4, Interventional, and Basic science

Why this study was suspended
Difficulty with enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
Up to 4 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 204 studies testing lidocaine in Pain — 19 open to participants now, 19 under way, 1 of them phase 3. Lidocaine · Pain.

Planned enrollment
187th of 203
11 · median 66
Started
2008
with 17 others
Phase 4
63 of 204
6 open now
Registered
27th of 204
by date

Among the 204 studies testing lidocaine in Pain, this one is the 187th largest by planned enrollment of the 203 interventional ones that give a count, is one of 18 that started in 2008, is one of 63 in phase 4, and was the 27th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

19 of the 204 studies testing lidocaine in Pain are open now, in 9 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About lidocaine

Lidocaine: first FDA approval 1948 (XYLOCAINE), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: Up to 4 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 204 studies testing lidocaine in Pain, or all of them as a file.
02

Study summary

This study will measure the amount of lidocaine and tetracaine in the blood after a 30 minute application of Synera.

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
Up to 4 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be an infant of 1 to 4 months of age and weigh at least 2.5 kg or a neonate of 0 to 4 weeks postnatal age with a gestation period of at least 37 weeks, and weigh at least 1.8 kg.
  • Subject is scheduled to have a medically indicated minor superficial procedure for which topical local anesthesia would provide a benefit.
  • Subject has or will have an indwelling vascular access catheter for blood sampling at the time of the procedure visit. The indwelling vascular access catheter placement must be necessary for medical reasons other than the purposes of this study.
  • The additional blood draws for the purposes of this study do not pose more than a minor risk to the health and welfare of the subject.

Exclusion criteria

Exclusion Criteria:

  • Subject has known allergies or sensitivities to any component of Synera.
  • Subject has laboratory abnormalities.
  • Subject has known multiple allergies that could indicate hypersensitive skin.
  • Subject has known active atopic dermatitis at or near the patch application site.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (estimated)

Interventions

  • Druglidocaine 70mg and tetracaine 70mg topical patch

    Drug page: Lidocaine

    One Synera Patch applied for 30 minutes.

    Also known as: Synera

06

What researchers measure

Primary outcomes

  1. Evaluate the systemic exposure to lidocaine and tetracaine following application of Synera

    Time frame: 30 hours

Secondary outcomes

  1. Monitor the nature and frequency of adverse events

    Time frame: 30 Hours

07

Study locations

1 site
  • Children's National Medical Center
    Washington, District of Columbia 20010, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Apr 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2008
First posted
Sep 5, 2008
Start
Sep 2008
Primary completionEst.
Apr 2013
CompletionEst.
Apr 2013
Last update
Mar 23, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00747669
Lead sponsor
ZARS Pharma Inc.
Responsible party
Sponsor
First posted
Sep 5, 2008
Start date
Sep 2008
Primary completion
Apr 2013 (estimated)
Completion
Apr 2013 (estimated)
Last update
Mar 23, 2012

Study contacts

ZARS Clinical Development
study chair · ZARS Pharma

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion